dihexa fda approval status 2026 Retatrutide 2026: Everything We Know So Far Updated 2026 FDA Category 2
Description
It does not directly stimulate muscle growth the way anabolic hormones or growth hormone-releasing peptides are intended to
Some patients may experience slight soreness at the injection site or minor bruising, which typically resolves within 24-48 hours
Early assessment is important as ED can indicate underlying cardiovascular disease, diabetes, or hormonal imbalances
The practical focus is glucose, kidney function, lipids, GI tolerance, gallbladder/pancreas symptoms, and thyroid-history cautions
Because a 4.5 mg dose uses almost the entire vial, plan vial supply accordingly
